Navigation Links
Stanford Study Finds No Conclusive Benefit From Treating,Kleptomania With Medication

STANFORD, Calif.--(BUSINESS WIRE)--Mar 15, 2007 - A small clinical trial of a medication to treat kleptomania has failed to find any conclusive benefit for patients with the impulsive stealing disorder, according to researchers at the Stanford University School of Medicine.

But the results leave open the possibility that some medications, including the one in the trial, may still be an effective treatment for certain patients.

More than 1.2 million people in the United States are thought to suffer from kleptomania, the guilt-ridden, impulsive stealing of inexpensive and unneeded items. The condition differs from shoplifting, in which the action is usually planned and motivated by need or monetary gain. People suffering from kleptomania often fail to seek treatment for fear of legal repercussions.

The medication in the trial was escitalopram, marketed as Lexapro. The drug belongs to a class of antidepressants known as selective serotonin reuptake inhibitors, and earlier studies have suggested that SSRIs can be effective in treating some impulse control disorders, such as skin picking. In an earlier, non-blinded open-label phase of the kleptomania study, when trial participants were aware that they were taking escitalopram and not a placebo, 78 percent of the patients responded to the drug.

In the second phase of the study, conducted as a double-blind, placebo-controlled trial, the benefit was not seen.

"When we randomized people to drug vs. placebo, the same proportion of people relapsed on drug as relapsed on placebo, suggesting that it was really a placebo response in the initial phase of the study," said Lorrin Koran, MD, professor of psychiatry and behavioral sciences and first author of the study, which will be published in the March issue of the Journal of Clinical Psychiatry.

In the double-blind trial, 15 subjects were assigned to receive either a placebo or escitalopram . For both groups, the relapse rates were effectively the same, with three of seven patients on the drug relapsing, compared with four of eight on the placebo.

Koran says that the small number of subjects in the study makes it impossible to know with certainty whether the results of the trial are really indicative of the effectiveness of escitalopram.

"For some people, I think these drugs really do work. And for others, maybe not, but until you have large studies you can't tease that out," he said.

Koran emphasized that the results of the clinical trial are not definitive, and some people may be helped by therapy involving medication. For others, receiving psychological treatment, perhaps in combination with medication, may prove most effective. But regardless, he said, "People with this disorder should definitely seek treatment."

This study was funded by Forest Laboratories, which makes and markets Lexapro. Koran has served as a paid speaker for Forest Laboratories, as has second author Elais Aboujaoude, MD, clinical assistant professor of psychiatry and behavioral sciences and director of Stanford's Impulse Control Clinic. Nona Gamel, clinical research manager, was also a co-author on the study.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions -- Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at


Stanford University Medical Center
Louis Bergeron, 650-724-2454 (PRINT MEDIA)
M.A. Malone, 650-723-6912 (BROADCAST MEDIA)


Related medicine technology :

1. Stanford Researchers Find Brain Pathway of Depression in Rats
2. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
3. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
4. Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher
5. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
6. Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds
7. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
8. Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... toilets were," said an inventor from Hillside, N.J. "Many people catch diseases simply ... so that individuals will always be protected from germs." , He developed the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
Breaking Medicine News(10 mins):